We have a lot to talk about. Are you ready for RealTalk MS??!
Oral DMT Pronesimod Moves Closer to FDA Approval 5:29
Early Clinical Markers Are Clues to Aggressive MS 7:20
MS Depression Affects Specific Cognitive Functions 11:18
Laws are Changing for Family Caregivers 12:48
My Work with Embracing Carers and Time Counts 16:29
My Interview with Professor Catherine Lubetzki 19:06
Have a Minute? Leave Us a Rating & Review! 29:59
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.
Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
STUDY: Nueronal Vulnerability and Multilineage Diversity in Multiple Sclerosis
Jansenn Reports Positive Top-Line Phase 3 Results for Ponesimod in Adults with Relapsing Multiple Sclerosis
STUDY: Early Clinical Markers of Aggressive Multiple Sclerosis
STUDY: Dissociable Cognitive Patterns Related to Depression and Anxiety in Multiple Sclerosis
Give RealTalk MS a Rating & Review
Download the RealTalk MS App for iOS
Download the RealTalk MS App for Android
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 101
Hosted By: Jon Strum
Guest: Professor Catherine Lubetzki
Tags: MS, MultipleSclerosis, mssociety, MSResearch, MSIntFederation, caregiving, EmbracingCarers, EMDSerono